Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050947 · ClinicalTrials.gov registry record · Phase 3
Pediatric Epilepsy Study
A Phase 3 study of Epilepsy, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 94
- Enrollment target
- 20
- Study locations
NCT00050947: Completed Phase 3 study of Epilepsy, sponsored by Novartis Pharmaceuticals.
NCT00050947 is a Phase 3 study of Epilepsy that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 94 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050947, a Phase 3 study of Epilepsy, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 94 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
Conditions Studied
Interventions
- DRUG oxcarbazepine
Study Locations (20)
Ohio
- - Akron
- - Cincinnati
- - Cleveland
Alabama
- - Birmingham
- - Mobile
California
- - Madera
- - Orange
Florida
- - Miami
- - Tampa
Minnesota
- - Duluth
- - Saint Paul
Missouri
- - Chesterfields
- - St Louis
New York
- - Buffalo
- - New York
Colorado
- - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-02 |
| Phase | Phase 3 |
What the finished NCT00050947 record still lists
NCT00050947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which oxcarbazepine is the first listed.
NCT00050947 names 20 study sites across 12 states, led by Ohio, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00050947 about?
NCT00050947 is a clinical study titled "Pediatric Epilepsy Study". This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
What is the current status of trial NCT00050947?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 94 participants. The study started on 2002-07. Estimated completion is 2004-02.
What conditions does trial NCT00050947 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00050947?
The interventions under investigation include: oxcarbazepine (DRUG).
Who is sponsoring clinical trial NCT00050947?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00050947 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00050947's enrollment target sits among peer trials
94 60th of 160 higher than 101 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
IV Lacosamide: The Safety of Intravenous Lacosamide
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia